Study of GDF15's impact on energy balance and inflammation has led to clinical development of GDF15‐mimetics for obesity and metabolic syndrome and GDF15‐inhibitors or antagonists for cancer‐related cachexia, immunosuppression and heart disease [11]. The gene discussed is GDF15; the disease is obesity due to melanocortin 4 receptor deficiency.